Bristol-Myers Squibb acquired an exclusive license for Novo Nordisk’s discovery biologics research program.
Bristol-Myers Squibb (BMS) announced on Mar. 24, 2015 that it reached an agreement to acquire an exclusive global license to Novo Nordisk’s discovery biologics research program focused on autoimmune diseases; however, the details of the agreement were not disclosed. The research program is designed to modulate the innate immune system as a therapy for autoimmune diseases.
Advertisement
With the acquisition, BMS expands its immunoscience and immuno-oncology research platform. The company saw success in this area of research earlier in 2015 when one of its late-stage studies for Opdivo (nivolumab) was ended early due to superior overall survival.
